Interleukin-12 (IL-12) is a potent inﬂammatory cytokine that exhibits broad acting immunomodulatory eﬀects including the activation and proliferation of T and NK cells, induction of Th1 diﬀerentiation, inhibition or reprogramming of suppressive cells such as TAMs and Tregs, and induction of MHC-I expression on tumour cells (Figure 1). While IL-12 displays remarkable anti-tumour activity in syngeneic tumour models, its clinical development has been hampered by severe toxicities associated with the activation of circulating immune cells. Here, we present a series of reduced potency IL-12 Fc fusion proteins engineered to minimise toxicity whilst retaining on-tumour activity and exhibiting an enhanced pharmacokinetic proﬁle.
- A series of human IL-12 Fc reduced potency variants were generated in a monovalent Fc fusion format.
- Reduced potency IL-12 Fc variants demonstrate superior pharmacokinetics and exhibit robust anti-tumour activity in in vivo models, whilst reducing toxicity associated with the activation of circulating immune cells.
- Compared to WT IL-12 Fc, reduced potency variants increase the levels of proinﬂammatory cytokines (e.g. IFN-ɣ) in the tumour relative to the periphery, indicating that potency reductions in IL-12 are associated with an increase in its therapeutic index.
For the full poster PDF click here or on the image below.